Pharmaceuticals

CR Sanjiu

JD Health and China Resources Sanjiu Collaborate to Extend TCM Services to Grassroots

CR Pharm 华润三九 Q1 2026 Revenue 8.13B yuan, Net Profit 1.209B yuan

CR Sanjiu released FY2026 Q1 earnings on April 24 During-Market (BJT), actual revenue CNY 8.13 B (forecast CNY 6.79 B), actual EPS CNY 0.65 (forecast CNY 0.6298)

CR Sanjiu to Release FY2026 Q1 Earnings on April 25 During-Market (BJT), Forecast Revenue CNY 6.79 B, EPS CNY 0.6298

CR Sanjiu to release FY2025 earnings on March 21 After-Market (BJT), forecast revenue CNY 30.9 B, EPS CNY 2.0405

CR Sanjiu released FY2025 Q4 earnings on February 6 After-Market (BJT), actual revenue CNY 9.616 B (forecast CNY 8.239 B), actual EPS CNY 0.6388 (forecast CNY 1.1348)

CR Sanjiu released FY2025 annual earnings on February 6 After-Market (BJT), actual revenue CNY 31.63 B (forecast CNY 30.9 B), actual EPS CNY 2.06 (forecast CNY 2.0405)

CR Sanjiu released FY2024 9 Months Earnings on October 24 After-Market (BJT), actual revenue CNY 19.74 B, actual EPS CNY 1.7798

CR Sanjiu released FY2024 Q3 earnings on October 24 After-Market (BJT), actual revenue CNY 5.634 B (forecast CNY 6.562 B), actual EPS CNY 0.3387 (forecast CNY 0.4588)

CR Sanjiu released FY2025 Q3 earnings on October 24 After-Market (BJT), actual revenue CNY 7.176 B (forecast CNY 7.279 B), actual EPS CNY 0.3277 (forecast CNY 0.3962)

CR Sanjiu released FY2025 9 Months Earnings on October 24 After-Market (BJT), Actual Revenue CNY 21.99 B, Actual EPS CNY 1.4138

CR Sanjiu to Release FY2025 Q3 Earnings on October 25 After-Market (BJT), Forecast Revenue CNY 7.279 B, EPS CNY 0.4124

CR Sanjiu released FY2025 Semi-Annual earnings on August 15 During-Market BJT, actual revenue CNY 14.81 B, actual EPS CNY 1.09

CR Sanjiu released FY2025 Q2 earnings on August 15 During-Market (BJT), actual revenue CNY 7.957 B (forecast CNY 7.582 B), actual EPS CNY 0.3245 (forecast CNY 0.676)

CR Sanjiu released FY2024 semi-annual earnings on August 15 After-Market (BJT), actual revenue CNY 14.11 B, actual EPS CNY 1.44

China Resources Sanjiu Acquires Exclusive Rights to ONC201, Strategic Decision Validates

CR Sanjiu to Release FY2025 Semi-Annual Earnings on August 16, 2025 (BJT)

Borui Pharmaceutical and China Resources Sanjiu Enter into Collaboration Agreement for BGM0504 Injection

China Resources Sanjiu's ESG Rating Upgraded to AAA

China Resources Sanjiu Reports Weakened Q1 2025 Earnings, Completes Tianyi Equity Acquisition

01666

00570

03613

000999

159849

512010

159992

520880

159929

Recently, the National Chinese Herbal Pieces Alliance Procurement Office released centralized procurement documents, proposing to purchase 41 varieties of Chinese herbal pieces, categorized into two specification grades: selected goods and unified goods. This procurement follows the principles of 'stabilizing clinical use, ensuring quality, opposing internal competition, and preventing bid rigging,' led by the Shandong Medical Security Bureau, and is expected to reshape a market valued at 300 billion yuan

Wallstreetcn

TONG REN TANG

TRAD CHI MED

TONGRENTANGCM

E Fund CSI HK Equities Medical and Health Integration ETF

Taikang CNI Public Health and Medical Health ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Minsheng Royal CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Universal 800 Health Care ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

GF CSI All Share Health Care ETF

New Progress in Centralized Procurement of Chinese Herbal Pieces: 41 Varieties Included, 300 Billion Market Landscape to Change

159316

510660

516820

03320

588130

China Resources Pharma announced that its subsidiary CR Sanjiu achieved an annual revenue of RMB 31.603 billion (the same below) for the year ending last December, an increase of 14.4% year-on-year. The net profit was RMB 3.421 billion, an increase of 1.58% year-on-year; the net profit excluding non-recurring items was RMB 3.134 billion, an increase of 0.5% year-on-year; earnings per share were RMB 2.06. A cash dividend of 59 cents (tax included) per share will be distributed to all shareholders of CR Sanjiu

AASTOCKS

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Tianhong CNI BIOMEDICINE ETF

Guotai CSI Bio-medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

China Southern Hang Seng Biotech ETF(QDII)

ICBCCS SSE STAR Biology and Medicine ETF

CHINARES PHARMA

Penghua SSE STAR Biology and Medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

E Fund CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

China Resources Pharmaceutical's subsidiary CR Sanjiu's annual net profit increased by 1.6% to 3.421 billion RMB

China Resources Pharmaceutical announced that its subsidiary China Resources Sanjiu's preliminary performance for the year 2025 shows total operating revenue of RMB 31.629 billion, an increase of 14.5% year-on-year. Net profit attributable to shareholders is RMB 3.422 billion, an increase of 1.6%

CR Sanjiu, a subsidiary of CHINARES PHARMA, reported a net profit of 3.422 billion RMB for the year, an increase of 1.6%

CR Sanjiu Pharmaceutical Co., Ltd. recently increased its registered capital from approximately 1.28 billion yuan to approximately 1.66 billion yuan, an increase of about 30%. The company was established in 1999, with Eric Wu as the legal representative. Its business scope includes the cultivation of traditional Chinese medicinal materials and the import and export of related machinery and raw materials

36Kr

CR Sanjiu's registered capital increased to approximately 1.66 billion yuan

CR Sanjiu(000999.SZ)

New Progress in Centralized Procurement of Chinese Herbal Pieces: 41 Varieties Included, 300 Billion Market Landscape to Change

China Resources Pharmaceutical's subsidiary CR Sanjiu's annual net profit increased by 1.6% to 3.421 billion RMB

CR Sanjiu, a subsidiary of CHINARES PHARMA, reported a net profit of 3.422 billion RMB for the year, an increase of 1.6%

CR Sanjiu's registered capital increased to approximately 1.66 billion yuan